Title

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

Document Type

Article

Publication Title

Vaccines

Abstract

AIM: To determine the relationship between gene expression profile (GEP) and overall survival (OS) by NanoString following treatment with Vigil. PATIENTS AND METHODS: Recurrent ovarian cancer patients ( = 21) enrolled in prior clinical trials. RESULTS: GEP stratified by TIS vs. TIS demonstrated OS benefit (NR vs. 5.8 months HR 0.23; = 0.0379), and in particular, MHC-II elevated baseline expression was correlated with OS advantage ( = 0.038). Moreover, 1-year OS was 75% in TIS patients vs. 25% in TIS ( = 0.03795). OS was also correlated with positive γ-IFN ELISPOT response, 36.8 vs. 23.0 months (HR 0.19, = 0.0098). CONCLUSION: Vigil demonstrates OS benefit in correlation with TIS score, elevated MHC-II expression and positive γ-IFN ELISPOT in recurrent ovarian cancer patients.

DOI

10.3390/vaccines9080894

Publication Date

8-12-2021

Share

COinS